Tumor-agnostic therapy developer Black Diamond Therapeutics Inc. has completed an oversubscribed series C financing of $85 million. The Cambridge, Mass.-based company said proceeds will help it advance candidates targeting oncogenic driver mutations of the ErbB kinases in EGFR and HER2, starting with a combined phase I/II trial of its most advanced candidate next year.
Spinal cord stimulation to treat pain has long been associated with mixed efficacy and substantial side effects such as paresthesia, which is an unpleasant tingly or prickly sensation. Redwood City, Calif.-based Nevro Corp. famously has built a multi-billion-dollar business on next-gen, pain neurostimulation technology that improves efficacy and reduces side effects. Sommerville, Mass.-based Micro-leads Medical Inc. hopes that it could be next in successfully further refining spinal cord stimulation.
Menlo Park, Calif.-based Akoya Biosciences Inc. has scooped up $50 million in financing, with an eye toward growing via the expansion of commercial and operational resources and continuing product development activities around its platforms for spatial biology.
DUBLIN – 4Teen4 Pharmaceuticals GmbH raised €6.9 million (US$7.7 million) in a series A round to take procizumab, a first-in-class inhibitor of circulating dipeptidyl-peptidase 3 (cDPP3), into clinical trials for patients with cardiogenic shock.
Civetta Therapeutics LLC will take a $53 million series A to advance its platform and programs based on beta-propeller proteins that mediate protein-to-protein interactions. Those proteins can become involved in cancers, neurodegeneration and metabolic disorders, with oncology being the company’s initial focus.
BEIJING – Infection diagnostics specialist Genskey Technologies Co. Ltd., of Beijing, closed a series B financing round to secure ¥100 million (US$14 million) to advance pathogen testing using next generation sequencing. The series B round was joined by SB China Capital, Shanghai Lin Chong Investment Management, and Juyuan Capital.
DUBLIN – Imcheck Therapeutics SAS raised €48 million (US$53.2 million) in a series B financing round to move a pipeline of antibodies targeting gamma delta T cells into the clinic.
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.
RSS
